Prenylamine
General information:
| Withdrawn ID: | w59 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | C01DX02 |
| Molecular Formula: | C24H27N |
| Molweight: | 329.478 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | Yes |
|---|---|
| First approved: | 1960 |
| First death: | 1988 |
| First withdrawn: | 1989 |
| Last withdrawn: | 1989 |
| Reference: | https://www.ncbi.nlm.nih.gov/pubmed/2241409 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Prenylamine as primary suspect: | 2 |
|---|
Reported final outcomes:
Reported side-effects:
| Side-effect | Case number |
|---|---|
| Hyperkalaemia | 2 |
| Photosensitivity reaction | 1 |
| Off label use | 1 |
| Acute kidney injury | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| Q12809 | 65 | Potassium voltage-gated channel subfamily H member 2 | KCNH2_HUMAN |
| Q14524 | 2520 | Sodium channel protein type 5 subunit alpha | SCN5A_HUMAN |
Toxicity information:
| Toxicity class: | 3 |
|---|---|
| Toxicity type: | cardiovascular |
| LD50: | 225 mg/kg |
External links:
| ChEBML: | CHEMBL24072 |
|---|---|
| DrugBank: | DB04825 |